NASDAQ$PODD
Insulet Corp. · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Insulet reported a revenue increase of 27% year-over-year in Q1 2021.
Insulet reported strong first quarter results with revenue reaching $252.3 million, a 27.4% increase compared to the prior year. The company achieved the high end of its guidance, driven by growth in Omnipod and Drug Delivery revenues. Insulet is excited for the commercial launch of Omnipod 5.
- First quarter revenue increased by 27.4% to $252.3 million.
- Total Omnipod revenue grew by 22.9% to $233.2 million.
- U.S. Omnipod revenue increased by 22.9% to $143.3 million.
- Drug Delivery revenue increased by 130.1% to $19.1 million.
Headline financials
Revenue & EPS history
Insulet · Revenue · Quarterly
$252M
Revenue by segment
Insulet · $252M total across 3 segments · Q1 2021
- U.S. Omnipod$143M+22.9%56.8%
- International Omnipod$89.9M+23.0%35.6%
- Drug Delivery$19.1M+130.1%7.6%
Forward guidance
For the year ending December 31, 2021, the Company is raising the low end of its revenue guidance range to 16% to 20% (previously 15% to 20%). For the quarter ending June 30, 2021, the Company expects revenue growth of 10% to 14%.
Tailwinds
- Total Omnipod revenue growth of 18% to 21% (previously 17% to 21%) for the year ending December 31, 2021.
- U.S. Omnipod revenue growth of 22% to 25% (previously 21% to 25%) for the year ending December 31, 2021.
- International Omnipod revenue growth of 11% to 15% (previously from 10% to 15%) for the year ending December 31, 2021.
- Total Omnipod revenue growth of 14% to 17% for the quarter ending June 30, 2021.
- U.S. Omnipod revenue growth of 17% to 20% for the quarter ending June 30, 2021.
Headwinds
- Drug Delivery revenue growth of (11)% to 4% for the year ending December 31, 2021.
- Drug Delivery revenue growth of (24)% to (16)% for the quarter ending June 30, 2021.
- Currency impact is expected to affect international Omnipod revenue growth by 6% for the year ending December 31, 2021.
- Currency impact is expected to affect total Omnipod revenue growth by 2% for the year ending December 31, 2021.
- Currency impact is expected to affect total revenue growth by 2% for the year ending December 31, 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
+3.0%
Avg return
Earnings day
+4.0%
Avg return
5 days after
+5.2%
Avg return
30 days after
65%
41 / 63 earnings
Positive
+20.7%
Q1 2025
Best reaction
-16.8%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.1% | +3.8% | +1.4% | |
| Q4 2025 | +3.5% | +1.2% | -7.8% | |
| Q3 2025 | +2.8% | +3.8% | -3.2% | |
| Q1 2025 | +20.7% | +25.1% | +21.3% | |
| Q4 2024 | -1.9% | -6.1% | -6.9% | |
| Q3 2024 | +12.0% | +15.0% | +10.9% | |
| Q2 2024 | -4.3% | +2.2% | +12.8% | |
| Q1 2024 | -5.5% | -1.9% | +9.0% | |
| Q4 2023 | -4.3% | -13.4% | -14.6% | |
| Q3 2023 | +18.1% | +17.5% | +39.6% | |
| Q2 2023 | -11.9% | -13.6% | -31.6% | |
| Q1 2023 | +2.4% | -0.4% | -12.4% | |
| Q4 2022 | +2.3% | -4.0% | +7.8% | |
| Q3 2022 | +19.6% | +16.3% | +17.7% | |
| Q2 2022 | +2.4% | -0.8% | -2.5% | |
| Q1 2022 | -16.8% | -23.0% | -13.9% | |
| Q4 2021 | +8.9% | +12.9% | +7.4% | |
| Q3 2021 | -1.3% | +2.0% | -15.6% | |
| Q2 2021 | -1.3% | +0.1% | +8.4% | |
| Q1 2021 | -11.4% | -13.0% | +2.8% | |
| Q4 2020 | +2.3% | +1.0% | +1.0% | |
| Q3 2020 | +14.6% | +14.4% | +16.0% | |
| Q2 2020 | +1.1% | -7.7% | -4.9% | |
| Q1 2020 | +5.4% | +6.8% | -13.3% | |
| Q4 2019 | -13.2% | -8.4% | -14.2% | |
| Q3 2019 | +9.9% | +16.4% | +26.5% | |
| Q2 2019 | +18.4% | +26.0% | +30.0% | |
| Q1 2019 | +14.0% | +20.9% | +29.4% | |
| Q4 2018 | +5.1% | +7.7% | +6.6% | |
| Q3 2018 | +0.4% | -2.4% | -4.9% | |
| Q2 2018 | +2.4% | +2.6% | +24.3% | |
| Q1 2018 | -3.6% | -4.3% | +9.0% | |
| Q4 2017 | +3.6% | -1.1% | +8.6% | |
| Q3 2017 | +18.9% | +22.7% | +21.0% | |
| Q2 2017 | +6.5% | +8.6% | +15.5% | |
| Q1 2017 | -5.8% | -4.6% | +0.9% | |
| Q4 2016 | -5.2% | +0.7% | -7.2% | |
| Q3 2016 | +9.9% | +10.3% | +3.9% | |
| Q2 2016 | +18.5% | +23.3% | +22.2% | |
| Q1 2016 | -4.0% | — | — | |
| Q4 2015 | +9.0% | — | — | |
| Q3 2015 | +13.2% | — | — | |
| Q2 2015 | +10.0% | — | — | |
| Q1 2015 | -11.0% | — | — | |
| Q4 2014 | -4.5% | — | — | |
| Q3 2014 | +5.1% | — | — | |
| Q2 2014 | -2.2% | — | — | |
| Q1 2014 | -14.0% | — | — | |
| Q3 2013 | -3.4% | — | — | |
| Q2 2013 | +10.2% | — | — | |
| Q1 2013 | +12.0% | — | — | |
| Q4 2012 | +9.3% | — | — | |
| Q3 2012 | +4.2% | — | — | |
| Q2 2012 | +4.8% | — | — | |
| Q1 2012 | +2.1% | — | — | |
| Q4 2011 | -3.5% | — | — | |
| Q3 2011 | +0.5% | — | — | |
| Q2 2011 | +2.9% | — | — | |
| Q1 2011 | +0.6% | — | — | |
| Q4 2010 | -2.0% | — | — | |
| Q3 2010 | +2.5% | — | — | |
| Q2 2010 | +0.3% | — | — | |
| Q1 2010 | +11.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro